124 related articles for article (PubMed ID: 16082185)
1. In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595.
Qu CF; Songl YJ; Rizvi SM; Li Y; Smith R; Perkins AC; Morgenstern A; Brechbiel M; Allen BJ
Cancer Biol Ther; 2005 Aug; 4(8):848-53. PubMed ID: 16082185
[TBL] [Abstract][Full Text] [Related]
2. Targeted alpha therapy approach to the management of pancreatic cancer.
Allen BJ; Rizvi SM; Qu CF; Smith RC
Cancers (Basel); 2011 Apr; 3(2):1821-43. PubMed ID: 24212784
[TBL] [Abstract][Full Text] [Related]
3. Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model.
Song EY; Qu CF; Rizvi SM; Raja C; Beretov J; Morgenstern A; Apostolidis C; Bruchertseifer F; Perkins A; Allen BJ
Cancer Biol Ther; 2008 Jan; 7(1):76-80. PubMed ID: 18347423
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
Kelly MP; Lee FT; Tahtis K; Smyth FE; Brechbiel MW; Scott AM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5604s-5612s. PubMed ID: 17875796
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer.
Qu CF; Song EY; Li Y; Rizvi SM; Raja C; Smith R; Morgenstern A; Apostolidis C; Allen BJ
Clin Exp Metastasis; 2005; 22(7):575-86. PubMed ID: 16475028
[TBL] [Abstract][Full Text] [Related]
6. MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate.
Qu CF; Li Y; Song YJ; Rizvi SM; Raja C; Zhang D; Samra J; Smith R; Perkins AC; Apostolidis C; Allen BJ
Br J Cancer; 2004 Dec; 91(12):2086-93. PubMed ID: 15599383
[TBL] [Abstract][Full Text] [Related]
7. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
[TBL] [Abstract][Full Text] [Related]
8. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
Nikula TK; McDevitt MR; Finn RD; Wu C; Kozak RW; Garmestani K; Brechbiel MW; Curcio MJ; Pippin CG; Tiffany-Jones L; Geerlings MW; Apostolidis C; Molinet R; Geerlings MW; Gansow OA; Scheinberg DA
J Nucl Med; 1999 Jan; 40(1):166-76. PubMed ID: 9935073
[TBL] [Abstract][Full Text] [Related]
9. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
10. Targeted alpha therapy for cancer.
Allen BJ; Raja C; Rizvi S; Li Y; Tsui W; Zhang D; Song E; Qu CF; Kearsley J; Graham P; Thompson J
Phys Med Biol; 2004 Aug; 49(16):3703-12. PubMed ID: 15446799
[TBL] [Abstract][Full Text] [Related]
11. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.
Bloechl S; Beck R; Seidl C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7070s-7074s. PubMed ID: 16203804
[TBL] [Abstract][Full Text] [Related]
12. In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells.
Li Y; Wang J; Rizvi SM; Jager MJ; Conway RM; Billson FA; Allen BJ; Madigan MC
Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4365-71. PubMed ID: 16303921
[TBL] [Abstract][Full Text] [Related]
13. Treatment of lung tumor colonies with 90Y targeted to blood vessels: comparison with the alpha-particle emitter 213Bi.
Kennel SJ; Stabin M; Yoriyaz H; Brechbiel M; Mirzadeh S
Nucl Med Biol; 1999 Jan; 26(1):149-57. PubMed ID: 10096515
[TBL] [Abstract][Full Text] [Related]
14. 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice.
Beck R; Seidl C; Pfost B; Morgenstern A; Bruchertseifer F; Baum H; Schwaiger M; Senekowitsch-Schmidtke R
Cancer Sci; 2007 Aug; 98(8):1215-22. PubMed ID: 17561973
[TBL] [Abstract][Full Text] [Related]
15. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
McDevitt MR; Barendswaard E; Ma D; Lai L; Curcio MJ; Sgouros G; Ballangrud AM; Yang WH; Finn RD; Pellegrini V; Geerlings MW; Lee M; Brechbiel MW; Bander NH; Cordon-Cardo C; Scheinberg DA
Cancer Res; 2000 Nov; 60(21):6095-100. PubMed ID: 11085533
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models.
Sugyo A; Tsuji AB; Sudo H; Okada M; Koizumi M; Satoh H; Kurosawa G; Kurosawa Y; Saga T
PLoS One; 2015; 10(4):e0123761. PubMed ID: 25893775
[TBL] [Abstract][Full Text] [Related]
18. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
Wang L; Chen H; Pourgholami MH; Beretov J; Hao J; Chao H; Perkins AC; Kearsley JH; Li Y
PLoS One; 2011; 6(9):e24405. PubMed ID: 21931707
[TBL] [Abstract][Full Text] [Related]
19. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).
Ballangrud AM; Yang WH; Charlton DE; McDevitt MR; Hamacher KA; Panageas KS; Ma D; Bander NH; Scheinberg DA; Sgouros G
Cancer Res; 2001 Mar; 61(5):2008-14. PubMed ID: 11280760
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunoconjugates for targeted alpha therapy of malignant melanoma.
Abbas Rizvi SM; Sarkar S; Goozee G; Allen BJ
Melanoma Res; 2000 Jun; 10(3):281-9. PubMed ID: 10890383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
